AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31930222
Drug: DIVER‐100® (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DIVER‐100® (2 capsules/day for 10 days per month, for 3 months)
Trial: 29554535
Drug: escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram (10 mg twice/day) + CBX (200 mg twice/day)
Trial: 29554535
Drug: escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escitalopram (10 mg twice/day) + placebo (twice/day)
Trial: 24560438
Drug: Memantine 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 40 mg
Trial: 22234683
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 100 mg twice daily
Trial: 22234683
Drug: Enteric-coated aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated aspirin 200 mg once daily
Trial: 22234683
Drug: Plain aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain aspirin 100 mg once daily
Trial: 15209959
Drug: Fexofenadine HCl
RxNorm normalized name: fexofenadine HCl
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine HCl 30 mg b.i.d.
Trial: 15209959
Drug: Fexofenadine (any
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine (any dose)
Trial: 15209959
Drug: Any fexofenadine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Any fexofenadine doses
Trial: 11260249
Drug: Doxepin cream
RxNorm normalized name: doxepin Topical Cream
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin cream (5%) applied 4 times daily for 3 days
Trial: 11260249
Drug: Basic ointment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic ointment (control) applied 4 times daily for 3 days
Trial: 8047334
Drug: Spray application
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray application of 1% cyclopentolate hydrochloride
Trial: 8047334
Drug: Spray application
RxNorm normalized name: Inhalation Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spray application of cyclopentolate hydrochloride
Trial: 30888330
Drug: tablet+messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet+messages
Trial: 30888330
Drug: tablet only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet only
Trial: 28718233
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of 0.5% hyperbaric bupivacaine (Group A)
Trial: 28718233
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of 0.5% hyperbaric bupivacaine (Group B)
Trial: 23561946
Drug: Doxepin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (10 mg daily)
Trial: 23561946
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy with bright light therapy
Trial: 19549691
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg bid the day before and the day of the procedure plus saline i.v. 0.9% 1 ml/kg/h 12-24 h before and 24 h after the procedure)
Trial: 16700815
Drug: New insoluble-matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New insoluble-matrix retropalpebral ophthalmic insert containing 5.38 mg phenylephrine and 0.28 mg tropicamide
Trial: 16700815
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (insert and eye drops)
Trial: 16700815
Drug: New insoluble-matrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New insoluble-matrix retropalpebral ophthalmic insert
Trial: 10960643
Drug: Dinoprostone 0.5
RxNorm normalized name: dinoprostone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dinoprostone 0.5 mg every 6 hours (maximum four doses)
Trial: 8985996
Drug: Solution A
RxNorm normalized name: I.V. SOLUTION ADDITIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution A (Methenamine)
Trial: 8985996
Drug: Solution B
RxNorm normalized name: DONISLECEL-JUJN RINSE SOLUTION BAG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution B (blank solution)
Trial: 1462902
Drug: Lidocaine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (100 mg intravenous bolus followed by 300 mg intramuscular injection)
Trial: 3913425
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nicergoline (Sermion) daily for 180 days
Trial: 3913425
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg dihydroergotamine mesilate (DHETM) daily for 180 days
Trial: 19709504
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n = 10)
Trial: 12774159
Drug: Magnesium infusion
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium infusion (1 mmol/kg)
Trial: 9512843
Drug: Prophylactic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic epidural blood patch (PEBP) recommended by 37% of centres; more common in US than Canadian centres.
Trial: 9512843
Drug: Epidural blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blood patch (EBP) offered most commonly at or within 24 hours of diagnosis of post-dural puncture headache (PDPH).
Trial: 23998910
Drug: Isoflavone intake
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone intake (highest quartile Q4: 1.6‐78.8 mg/d)
Trial: 8159835
Drug: sulbactam/ampicillin 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sulbactam/ampicillin 1 g IV before surgical incision and then 8-hourly x 3 days
Trial: 8159835
Drug: cefuroxime 2
RxNorm normalized name: cefuroxime 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefuroxime 2 g IV before surgical incision and then 8-hourly x 3 days
Trial: 1683196
Drug: Chromium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chromium supplementation (600 micrograms daily divided into three doses)
Trial: 6749826
Drug: Amitriptyline-perphenazine (100/8-150/12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline-perphenazine (100/8-150/12 mg/day)
Trial: 6749826
Drug: Doxepin (100-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxepin (100-150 mg/day)
Trial: 29075343
Drug: Cerebrolysin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (30 mL over seven days followed by 10 mL until day 30)
Trial: 25359354
Drug: Immediate isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate isoniazid treatment
Trial: 25359354
Drug: Deferred isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deferred isoniazid treatment
Trial: 17072689
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with propofol/remifentanil/rocuronium (TIVA)
Trial: 10618560
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (goal dose 100 microgram/min)
Trial: 8939149
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg zileuton
Trial: 8939149
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg zileuton
Trial: 29878939
Drug: Personalized fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized fluid therapy using noninvasive cardiac output (Clearsight system) monitor
Trial: 29878939
Drug: Protocolized fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocolized fluid therapy approach
Trial: 27052531
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic Acid 400 μg/d
Trial: 27052531
Drug: Creatine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine plus Folic Acid 400 μg/d
Trial: 24314907
Drug: Small SZ
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small SZ subgroup not receiving antipsychotic medication (n=10)
Trial: 22425936
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (TTM tailored interventions)
Trial: 20061906
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg monthly intramuscular octreotide
Trial: 11535320
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine administered by needle-free jet injector (JI)
Trial: 11535320
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine administered by one JI device
Trial: 11535320
Drug: Trivalent inactivated
RxNorm normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent inactivated influenza vaccine administered by needle and syringe (N&S)
Trial: 9716243
Drug: Propentofylline (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propentofylline (300 mg t.i.d. taken 1 h before meals)
Trial: 8142094
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac 30 mg loading dose followed by IV ketorolac 15 mg every 6 hours (Group 2)
Trial: 8142094
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac 60 mg loading dose followed by IV ketorolac 30 mg every 6 hours (Group 3)
Trial: 3045341
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (20 mcg)
Trial: 3045341
Drug: Papaverine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papaverine (7.5 mg) plus Phentolamine (0.25 mg)
Trial: 21552726
Drug: Direct and
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct and indirect intervention (Therapy Group - TG)
Trial: 16542657
Drug: 125 mL
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL intravenous fluid per hour
Trial: 16542657
Drug: 250 mL
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL intravenous fluid per hour
Trial: 10352088
Drug: Omeprazole 2
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2 x 20 mg/day for 7 days (group A)
Trial: 10352088
Drug: Omeprazole 2
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 2 x 40 mg/day for 7 days (group B)
Trial: 10352088
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups continued treatment with omeprazole (40 mg/day days 8-14 and 20 mg/day days 15-28)
Trial: 29807102
Drug: Subetta add-on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subetta add-on therapy
Trial: 25503168
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg or 20 mg of melatonin
Trial: 16404981
Drug: IRS 19
RxNorm normalized name: irsogladine
DrugBank: Irsogladine (DB13056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IRS 19 vaccine
Trial: 10551433
Drug: Glycoprotein IIb/IIIa
RxNorm normalized name: GLYCOPROTEIN IIB/IIIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoprotein IIb/IIIa receptor antagonists (parenteral formulations)
Trial: 8607684
Drug: Low-dose aprotinin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose aprotinin (20,000 kIU/kg [2.8 mg/kg])
Trial: 1934206
Drug: Atracurium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.3 mg.kg‐1 (ED95)
Trial: 1934206
Drug: d-tubocurarine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-tubocurarine 0.3 mg.kg‐1 (ED90)
Trial: 18330955
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E therapy (Group 3)
Trial: 15511602
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen preparation composed of 17-beta estradiol
Trial: 1761453
Drug: Cefprozil, 500
RxNorm normalized name: Cefprozil, 500 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil, 500 mg once a day
Trial: 1761453
Drug: Cefaclor, 250
RxNorm normalized name: Cefaclor, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor, 250 mg three times a day
Trial: 6282790
Drug: Prophylactic cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic cranial irradiation (PCI) plus high dose CAV, methotrexate and leucovorin
Trial: 28489320
Drug: Aspirin (COX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (COX inhibition)
Trial: 15054441
Drug: Instant coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instant coffee (5 g, approximately 50 mg trigonelline)
Trial: 15054441
Drug: Trigonelline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trigonelline (50 mg)
Trial: 11166143
Drug: Conventional-dose therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose therapy
Trial: 8189732
Drug: Alcohol (actual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (actual and expected doses)
Trial: 2438221
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (VBP regimen)
Trial: 28034894
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml water ingestion
Trial: 28034894
Drug: Angiopoietin-1 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiopoietin-1 treatment
Trial: 28034894
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml normal saline ingestion
Trial: 28034894
Drug: 50 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ml water ingestion
Trial: 23819337
Drug: Genetically engineered
RxNorm normalized name: Genetically Engineered Herpes Simplex Virus
DrugBank: G207 (DB05827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically engineered biological agents (GEBAs), primarily rituximab (n = 66) and infliximab (n = 31)
Trial: 23819337
Drug: Genetically engineered
RxNorm normalized name: Genetically Engineered Herpes Simplex Virus
DrugBank: G207 (DB05827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically engineered biological agents (GEBAs)
Trial: 21694461
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D (after 8 weeks of low-dose vitamin D 1000 IU/day)
Trial: 21694461
Drug: Nasal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nasal insulin (60 IU qid for 48 hours after high-dose vitamin D)
Trial: 21694461
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after high-dose vitamin D)
Trial: 21694461
Drug: Placebo (after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (after nasal insulin)
Trial: 16153694
Drug: Intraperitoneal alpha-interferon
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal alpha-interferon (50 x 10(6) IU weekly for 6 doses)
Trial: 9377133
Drug: Cisapride (1.4‐2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (1.4‐2.3 mg/kg/day)
Trial: 8266226
Drug: 20 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 micrograms dose of hepatitis B vaccine
Trial: 8266226
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms dose of hepatitis B vaccine
Trial: 31114673
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) and home exercise
Trial: 31114673
Drug: Combination groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination groups (SMT + home exercise, supervised rehabilitative exercise + home exercise)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (rehabilitation)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (enabling)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (review)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (assessment)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (supportive)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (activity to support therapy)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (overall therapy received)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (delivery personnel)
Trial: 29990345
Drug: Speech and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech and language therapy (session type)
Trial: 27485453
Drug: CY 2
RxNorm normalized name: Clearskin Emergency 2 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CY 2 g/m(2) + G-CSF (arm A)
Trial: 24862733
Drug: HVAD and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HVAD and ICD therapy
Trial: 8100914
Drug: Low-dose allopurinol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose allopurinol (25 mg on alternative days) plus triple immunosuppression (cyclosporin, prednisolone, azathioprine)
Trial: 8100914
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy alone (cyclosporin, prednisolone, azathioprine)
Trial: 25603438
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution placebo
Trial: 23335738
Drug: Anidulafungin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (200 mg loading dose on day 1, followed by 100 mg daily maintenance dose)
Trial: 23335738
Drug: Anidulafungin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anidulafungin (150 mg daily maintenance dose for 240-kg patient)
Trial: 16835748
Drug: Octreotide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (30 mg) alone monthly
Trial: 16835748
Drug: Octreotide (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (30 mg) in combination with rofecoxib (up to 50 mg bid daily)
Trial: 9922303
Drug: OAC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC group (20 mg omeprazole, 1000 mg amoxicillin, 500 mg clarithromycin)
Trial: 9922303
Drug: OMC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OMC group (20 mg omeprazole, 400 mg metronidazole, 250 mg clarithromycin)
Trial: 9922303
Drug: AC group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AC group (1000 mg amoxicillin, 500 mg clarithromycin)
Trial: 9922303
Drug: MC group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MC group (400 mg metronidazole, 250 mg clarithromycin)
Trial: 7917508
Drug: Activated charcoal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal (25 g) administered immediately after astemizole ingestion
Trial: 7917508
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of activated charcoal (12 g) administered twice daily for 8 days
Trial: 31934821
Drug: Nattospes as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattospes as an adjuvant to standard of care (SOC) treatment
Trial: 31934821
Drug: Nattospes as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nattospes as an adjuvant to SOC treatment
Trial: 25156179
Drug: SPS-Mg
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPS-Mg
Trial: 21472620
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body vibration therapy (FitVibe medical™)